MedTrace Logo

Canagliflozin in Advanced Renal Disease With MRI Endpoints

NCT06182839 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2025-12-08

No results posted yet for this study

Summary

This is a phase II, proof of concept, placebo-controlled, randomized clinical trial, assessing the effect of canagliflozin on cardiac structure and function in patients with advanced renal disease, including those on maintenance dialysis.

Our primary aim is to determine the effect of canagliflozin on cardiac structure and function in patients with advanced chronic kidney disease (CKD), compared with placebo. We hypothesize that canagliflozin will improve left ventricular (LV) hypertrophy in patients with advanced CKD. Our secondary aims are to describe the effect of canagliflozin on other cardiac magnetic resonance imaging parameters and surrogate markers of efficacy in this population.

Conditions

  • ESRD, CKD Stage 4, CKD Stage 5

Interventions

DRUG

Canagliflozin 300Mg Tab

Patients will get 1 pill of Canagliflozin 300 mg daily for one year.

DRUG

Placebo

Patients will get 1 pill of placebo daily for one year.

Sponsors & Collaborators

  • Heart and Stroke Foundation of Canada

    collaborator OTHER

  • McGill University Health Centre/Research Institute of the McGill University Health Centre

    lead OTHER

Principal Investigators

  • Thomas Mavrakanas, MD · Research Institute of the McGill University Health Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2028-03-30
Completion
2029-03-30

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06182839 on ClinicalTrials.gov